Acute Exacerbation, Medicine, Chinese Traditional, Pulmonary Disease, Chronic Obstructive
Conditions
Keywords
Chronic Obstructive Pulmonary Disease, Acute exacerbation, Traditional Chinese medicine
Brief summary
This is a multi-center, randomized, double-blind, controlled trial to compare the efficacy of two therapies for patients with AECOPD. 378 subjects will be randomly assigned to one therapies (conventional drug, and the combination of conventional drug and TCM) for 14 days treatment. After the treatment period, subjects in two arms will be followed up for 4 weeks. The primary outcomes will include COPD Assessment Test (CAT), and secondary outcomes include treatment failure rate, treatment success rate, hospitalization time, hospital admission rate, endotracheal intubation rate, mortality and quality of life (COPD-PRO, SF-36).
Interventions
DRUGTCM and conventional drug
All patients were treated with medicine based on 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD. The Experimental group will receive TCM according to the TCM syndrome. Sanhanhuayin granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of external cold and internal fluid in 14 treatment days. Qingrehuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-heat congesting lung in 14 treatment days. Zaoshihuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-damp amassing in lung in 14 treatment days.
DRUGTCM placebo and conventional drug
All patients were treated with medicine based on 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD. The control group will receive TCM placebo according to the TCM syndrome. Placebo Sanhanhuayin granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of external cold and internal fluid in 14 treatment days. Placebo Qingrehuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-heat congesting lung in 14 treatment days. Placebo Zaoshihuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-damp amassing in lung in 14 treatment days.
Sponsors
Henan University of Traditional Chinese Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* A confirmed diagnosis of moderate to very severe AECOPD * Age between 40 and 80 years * Syndrome differentiation meets criteria of syndrome of external cold and internal fluid,syndrome of phlegm-heat congesting lung,or syndrome of phlegm-damp amassing in lung * Without participations in other interventional trials in the previous one month * With the informed consent signed
Exclusion criteria
* Pregnant and lactating women * Dementia, mental disorders and reluctant partners * Complicated with heart failure (NYHA Class IV), or Serious cardiac arrhythmias, or unstable hemodynamics * Current respiratory disorders other than COPD (e.g., bronchiectasis, active tuberculosis, pneumothorax, Pleural effusion, pulmonary thromboembolic, or Neuromuscular diseases affect respiratory movement function) * Combined tumor * Treated outside the hospital for more than 7 days * Need to carry out invasive mechanical ventilation respiratory failure * Complicated with serious hepatic and renal diseases (liver cirrhosis, portal hypertension, bleeding of varicose veins, dialysis, or renal transplantation) * Bedridden for various reasons * Allergic to the used medicine
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| COPD Assessment Test(CAT) | Change from baseline CAT score at day 0, 14 of the treatment phase, at day 14, 28 of the follow-up phase. | Using COPD Assessment Test ( CAT) to asses the impact of AECOPD on a person's life, and how this changes over time. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Treatment success rate | The numbers of treatment success at day 14 of the treatment phase. | — |
| Length of hospital stays | The length hospital stays in 14 Days of the treatment phase | length hospital stays will be recorded. |
| Readmission due to AECOPD | The numbers of readmission due to AECOPD in 28 Days of the followup phase. | Readmission due to AECOPD will be recorded. |
| Intubation rate | The numbers of intubation at day 4,7,10，14 of the treatment phase, at day 14, 28 of the follow-up phase. | Intubation will be recorded. |
| Treatment failure rate | The numbers of treatment failure at day 14 of the treatment phase. | — |
| Dyspnea | Change from Baseline in the mMRC at day 0, 4, 7, 10,14 of the treatment phase, at day 14, 28 of the follow-up phase. | Using modified Medical Research Council (mMRC) to asses the dyspnea of COPD, and how this changes over time. |
| SF-36 | Change from Baseline in the SF-36 at day 0,14 of the treatment phase, at day 14, 28 of the follow-up phase. | Using the MOS item short from health survey (SF-36) to asses the impact of COPD on a person's life, and how this changes over time. |
| COPD-PRO | Change from Baseline in the COPD-PRO at day 0,14 of the treatment phase, at day 14, 28 of the follow-up phase. | Using the COPD patient reported outcome scale (COPD-PRO) to asses the impact of COPD on a person's life, and how this changes over time. |
| Mortality | The numbers of mortality at day 14 of the treatment phase and day 28 of the follow-up phase. | — |
Contacts
Primary ContactHailong Zhang, doctor
Backup ContactJiansheng Li, doctor
Outcome results
None listed